“All sorts of things can happen when you’re open to new ideas and playing around with things.”
– Stephanie Louise Kwolek
Research in the Haslinger lab at the University of Groningen focuses on the understanding and engineering of biosynthetic pathways in plants and microbes. Our goal is to engineer microbial cell factories to produce natural products with pharmaceutical applications. The three main lines of research are (1) the de novo genome sequencing of microbes inhabiting medicinal plants; (2) the computational mining of genome sequences for biosynthetic enzymes and pathways; and (3) the design and engineering of recombinant pathways in model organisms such as Escherichia coli.
We strive to generate greener sources for fine chemicals and pharmaceuticals and contribute to building a sustainable bio-based economy. Sustainability is not only the main motivator for our research but also the framework for how we perform our research. As scientists we minimize our greenhouse gas emissions and our environmental footprint by conserving water and energy, minimizing the use of single-use plastics and adhering to the principles of green chemistry.
The Haslinger lab aims to provide an inclusive and supportive environment for creative thinking and personal growth. We build upon each other’s strengths to achieve our goals and engage in the process each step along the way.
We are interested in the internal microbiomes of medicinal plants, the so-called endophytic microbial communities. We study the composition of these communities in the context of the plant habitat; as well as the genomes of individual members of the community in order to explore their potential for secondary metabolite production.
We are interested in identifying genes and pathways that can be used for in vitro enzymatic cascades and recombinant microbial cell factories. We explore computational approaches to pre-select candidates based on sequence motifs and genomic context in order to reduce the number of candidates for experimental screening while covering a wide sequence space.
We strive to generate recombinant biosynthetic pathways for a more sustainable production of nutraceuticals, pharmaceuticals and fine chemicals. We develop and employ in vitro prototyping workflows to minimize the experimental workload and the use of resources such as growth media, chemicals and solvents for greener lab practices.
Our funding sources
start-up fund K. Haslinger
personal fellowship K. Haslinger
personal fellowships Ting He and Bo Peng